| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T217 |
0-68 |
Sentence |
denotes |
The rationale for using lopinavir is attributed to multiple studies. |
| T218 |
69-199 |
Sentence |
denotes |
Lopinavir exhibited an antiviral activity against SARS-CoV-2 virus in Vero E6 cells with an estimated EC50 value of 26.63 μM [85]. |
| T219 |
200-344 |
Sentence |
denotes |
Computational studies have also suggested that lopinavir may inhibit the viral main protease Mpro, perhaps by targeting its active site [86,87]. |
| T220 |
345-435 |
Sentence |
denotes |
Earlier, lopinavir exhibited in vitro activity against SARS-CoV-1 and MERS-CoV [88,89,90]. |
| T221 |
436-526 |
Sentence |
denotes |
It also showed beneficial effects in animal studies for the treatment of MERS-CoV [91,92]. |
| T222 |
527-688 |
Sentence |
denotes |
Furthermore, there is an evidence of some clinical benefit for lopinavir/ritonavir when used with ribavirin and/or INFs against MERS-CoV and SARS-CoV [88,93,94]. |
| T223 |
689-848 |
Sentence |
denotes |
Yet, coronavirus proteases, including Mpro, do not have a C2-symmetric protein architecture which is the target of lopinavir and all HIV-1 protease inhibitors. |
| T224 |
849-956 |
Sentence |
denotes |
This subsequently sheds doubts on the prospect of HIV-1 aspartate protease inhibitors in treating COVID-19. |
